Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.
Video content above is prompted by the following questions:
Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use
May 14th 2025New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.
Read More